Article Per Year (5 Year)
p-Index From 2021 - 2026
1.513
P-Index
This Author published in this journals
All Journal The Indonesian Journal of Infectious Diseases J-Dinamika: Jurnal Pengabdian Kepada Masyarakat SOCIAL CLINICAL PHARMACY INDONESIA JOURNAL Media Ilmiah Kesehatan Indonesia Neraca: Jurnal Ekonomi, Manajemen dan Akuntansi Medic Nutricia : Jurnal Ilmu Kesehatan Seroja Husada: Jurnal Kesehatan Masyarakat
piter, piter
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Dentistry Economics, Econometrics & Finance Education Health Professions Immunology & microbiology Languange, Linguistic, Communication & Media Medicine & Pharmacology Neuroscience Nursing Public Health Social Sciences Veterinary

Published : 11 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 5 Documents
Search
Journal : SOCIAL CLINICAL PHARMACY INDONESIA JOURNAL

 1 
PEMANTAUAN TERAPI OBAT PADA PASIEN GEA (Gastroenteritis Akut) LAPORAN KASUS di RUANG RAWAT INAP ANAK di RUMAH SAKIT “X piter, piter
SOCIAL CLINICAL PHARMACY INDONESIA JOURNAL Vol 2, No 1 (2017)
Publisher : Universitas 17 Agustus 1945 Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52447/scpij.v2i1.818

Abstract

Diare  masih  banyak  terjadi  di  dunia  dan  menyebabkan  4 % kematian anak pada tahun 2009. Di Indonesia angka morbiditas diare pada anak -anak mencapai 60  %  sampai  80  %  dan  setiap  anak mengalami diare  rata - rata  1,6  sampai  2  kali  setahun  dengan  kematian  rata-rata  3,4  per  mil  pertahun  pada  balita  dan  12,7 per mil  per  tahun  pada  bayi.  Kasus  diare  pada bayi menduduki tempat kedua atau 11 % setelah infeksi saluran pernafasan akut (ISPA) sebagai penyebab kematian (Betz, 2002).
Clinical Pharmacy Services at The Central Public Hospital "X" Luthfiana, Farisa; Astiani, Rangki; piter, piter; Sukartiningsih, Yulita
SOCIAL CLINICAL PHARMACY INDONESIA JOURNAL Vol 8, No 2 (2023)
Publisher : Universitas 17 Agustus 1945 Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52447/scpij.v8i2.7440

Abstract

Background: Pharmaceutical service is a direct and responsible service to patients related to pharmaceutical preparations with the aim of achieving definite results to improve the patient's quality of life.Objective: The aim is to find out how clinical pharmacy services are at “X” Hospital with eleven clinical pharmacyservice indicators based on Minister of Health Regulation Number 72 of 2016.Methods: The method used is descriptive, which aims to obtain a realistic and objective picture of pharmaceuticalservices at “X” Center General Hospital.Results: The results of the study found that eleven indicators of clinical pharmacy services were Assessment and Prescription Services, Tracing Drug Use History, Drug Reconciliation, Drug Information Services (PIO), Counseling, Visitation, Drug Therapy Monitoring (PTO), Drug Side Effects Monitoring (MESO), Evaluation Medication Use(EPO), Dispensing of Sterile Preparations, and Monitoring Blood Drug Levels (PKOD) have been carried out properly in accordance with Minister of Health Regulation No. 72 of 2016, except for PKOD because there is no request from the doctor or pharmacist's initiative to do so.
PEMANTAUAN TERAPI OBAT PADA PASIEN NEUROPATI DIABETIK Laporan Kasus di Ruang Rawat Rumah Sakit “X” piter, piter
SOCIAL CLINICAL PHARMACY INDONESIA JOURNAL Vol 1, No 2 (2016)
Publisher : Universitas 17 Agustus 1945 Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52447/scpij.v1i2.819

Abstract

Neuropati diabetik (ND) merupakan salah satu komplikasi kronis paling sering ditemukan pada diabetes melitus. Resiko yang dihadapi pasien diabetes melitus dengan neuropati diabetik antara lain ialah infeksi berulang, ulkus yang tidak sembuh-sembuh dan amputasi jari/kaki.Pasien Ny.Sy 63 tahun dengan BB 75 kg tercatat pada tanggal 20 November 2016 masuk Rumah Sakit “X” dengan keluhan utama badan pegal-pegal diseluruh tubuh, jari tangan dan kaki baal, pusing, BAB dan BAK tidak ada keluhan, telapak tangan dan kaki nyeri. Riwayat penyakit terdahulu Diabetes Mellitus tipe 2. Dan didiagosa oleh dokter Neuropati DM. Dari hasil pemeriksaan fisik pada tanggal 20 November 2016 nilai tekanan darahnya tinggi 140/90  mmHg. Pada hasil pemeriksaan Laboratorium mengalami peningkatan Trigliserida dan Gula darah sewaktu yang menandakan bahwa pasien menderita DM. Dan mengalami  penurunan Hematokrik yang menandakan terjadinya anemia. Pemantauan terapi obat harus terus dilakukan kepada pasien untuk meningkatkan rasionalitas penggunaan obat. Dan sebaiknya mempertimbangkan penggunaan obat DM pada pasien, karena sewaktu-waktu gula darah pasien bisa meningkat, sebaiknya obat DM (Glibenklamid) tetap diminum selama perawatan. Memberikan edukasi kepada pasien agar memperbaiki lifestyle sepeti tidak merokok, minum alkohol, mengurangi konsumsi makanan yang banyak mengandung garam, kolestrol dan mengurangi aktifitas fisik untuk mencegah kekambuhan atau keparahan penyakit
DRUG THERAPY IN PATIENTS WITH GRADE 4 DEXTRA HIP OSTEOARTHRITIS WITH COMORBID HYPERTENSION AND TYPE 2 DIABETES MELLITUS Astiani, Rangki; Piter, Piter; Anggraeni, Ria; Luthfiana, Farisa; Sari, Dini Permata; Ramatillah, Diana Laila; Khan, Khasif
SOCIAL CLINICAL PHARMACY INDONESIA JOURNAL Vol 10, No 2 (2025)
Publisher : Universitas 17 Agustus 1945 Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52447/scpij.v10i2.8977

Abstract

Osteoarthritis (OA) is a chronic degenerative disease that affects the joints, especially heavy joints such as the knees and hips. OA often causes chronic pain and limited mobility, which is even more complex when accompanied by comorbid hypertension and type 2 diabetes mellitus. These comorbidities increase the risk of pharmacotherapy side effects and drug interactions, requiring a multidisciplinary approach and careful clinical pharmacy monitoring. The purpose of this report is to review the pharmacotherapy management of grade 4 OA Hip Dextra with comorbid HT and DMT2, assessing the safety, effectiveness, and role of clinical pharmacists in therapy optimization. A retrospective case study was conducted by analyzing the patient's medical records, including anamnesis, physical examination, laboratory, pharmacological therapy, and clinical response. The analysis was conducted based on the national guidelines of the Indonesian Ministry of Health, the 2021 National Formulary, PERKENI 2023, and PAPDI 2021. The patient was given combination therapy of NSAIDs, analgesics, prophylactic antibiotics, muscle relaxants, gastric protection, and supplementation for anemia. Therapeutic adjustments were made according to the patient's response and laboratory parameters. Clinical pharmacy monitoring ensures pain control, mobility, hemoglobin, and blood sugar. A multidisciplinary approach based on national guidelines has been shown to improve the safety and effectiveness of OA therapy with multiple comorbidities.
ANALYSIS OF CHEMOTHERAPY COSTS IN BREAST CANCER PATIENTS PARTICIPATING BPJS AT DHARMAIS CANCER HOSPITAL JAKARTA Piter, Piter; Astiani, Rangki; Monica, Kristin; Permatasari, Yuri
SOCIAL CLINICAL PHARMACY INDONESIA JOURNAL Vol 10, No 2 (2025)
Publisher : Universitas 17 Agustus 1945 Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52447/scpij.v10i2.7773

Abstract

This study aims to find out how much chemotherapy costs for inpatient breast cancer chemotherapy patients participating in BPJS and whether there is a difference in real hospital costs compared to INA-CBGs rates. This research is a descriptive, observational study taken from secondary data, in the form of medical record data, laboratory data, INA-CBGs e-claim data and financial data on patient medical costs in accordance with the inclusion and exclusion criteria totaling 100 patient data. Data analysis uses One Sample T-test to see whether there is a significant difference between real costs and INA-CBGs rates. Based on the results of the One Sample T-test, it shows that there is a significant difference. According to the statistical results, a significance of p<0.005 was obtained in class 3 and there was no significant difference in class 1 or class 2. The average cost that breast cancer patients have to pay for each procedure chemotherapy, severity level I Rp. 7,129,348, severity level II Rp. 9,323,275 and severity level III Rp. 9,037,426.
Co-Authors Anggraini Adhisty, Weny Astiani, Rangki Aviatin, Memy Farisa Luthfiana Fitriani Maskur, Nur Indrawan, Andhika Khan, Khasif Maylinda, Tashya Dhela Monica, Kristin Nasir Badu, Muhammad Nurfadilla, Nurfadilla Nurul Hadi Ovie Meizaradela Permatasari, Yuri Ramatillah, Diana Laila Ria Anggraeni Romadan, Rizki Sari, Dini Permata Siahaan, Selma Arsit Selto Sukartiningsih, Yulita Susilo, Aliyah Utami A, Widyanti Victoria, Brigita Zakiyah, Andi Mawaddah